The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis

Published:2019-11-06 Issue:5 Volume:235 Page:4913-4927
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Wang Chengdi¹^ORCID,Qiao Wenliang²^ORCID,Jiang Yuting³^ORCID,Zhu Min¹^ORCID,Shao Jun¹^ORCID,Wang Tao¹^ORCID,Liu Dan¹^ORCID,Li Weimin¹^ORCID

Affiliation:

1. Department of Respiratory and Critical Care Medicine, West China Hospital, West China Medical School Sichuan University Chengdu China

2. Department of Lung Cancer Center, Laboratory Lung Cancer, West China Hospital, West China Medical School Sichuan University Chengdu China

3. Department of Obstetrics and Gynecology, West China Medical School Sichuan University Chengdu China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.29371

Reference49 articles.

1. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

2. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

3. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

4. Borghaei H. David Hellmann M. Paz‐Ares G. Ramalingam L. S. Reck M S. John O'Byrne K. …Brahmer J.(2018).Nivolumab (Nivo) + platinum‐doublet chemotherapy (Chemo) vs chemo as first‐line (1L) treatment (Tx) for advanced non‐small cell lung cancer (NSCLC) with <1% tumor PD‐L1 expression: Results from CheckMate 227.Journal of Clinical Oncology 2018;36:9001.

5. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer;Advanced Science;2024-09-05

2. Relationship between the combination of platelet count and neutrophil‐lymphocyte ratio and prognosis of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study;Thoracic Cancer;2024-08-28

3. Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by¹⁸F-BMS-986192 PET: pooled analysis of data from four solid tumor types;Journal for ImmunoTherapy of Cancer;2024-06

4. Unlocking the potential: A novel prognostic index signature for acute myeloid leukemia;Computers in Biology and Medicine;2024-05

5. Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials;Nature Reviews Clinical Oncology;2024-04-10